Whole Genome Sequencing (WGS) Market Size, Share, Growth, and Industry Analysis, By Type (Large Whole-Genome Sequencing (> 5 Mb),Small Genome Sequencing (? 5 Mb)), By Application (Humanity,Plant,Animal), Regional Insights and Forecast to 2035

Whole Genome Sequencing (WGS) Market Overview

The global Whole Genome Sequencing (WGS) Market size is projected to grow from USD 1227.88 million in 2026 to USD 1432.94 million in 2027, reaching USD 49382.1 million by 2035, expanding at a CAGR of 16.7% during the forecast period.

The Whole Genome Sequencing (WGS) Market recorded more than 3.8 million genomes sequenced globally in 2024, a rise of 42 percent compared with 2021 levels. Clinical diagnostics represented 58 percent of sequencing activities, followed by research applications at 32 percent and agriculture/animal genomics at 10 percent. Over 1,200 sequencing centers worldwide conducted large-scale operations, with Illumina platforms sequencing 65 percent of global genomes. Oxford Nanopore devices achieved over 20 percent of portable sequencing installations. In total, more than 50 petabytes of genomic data were generated in 2024, supporting advancements in healthcare, agriculture, and bioinformatics.

The USA contributed 37 percent of global sequencing activity in 2024, equivalent to 1.4 million genomes. Nearly 68 percent of US hospitals with genomic labs offered WGS for cancer diagnostics, while 45 percent provided prenatal sequencing services. NIH-funded projects supported more than 600,000 genome sequences in 2024 alone. The USA maintained 420 sequencing facilities, of which 60 percent operated with Illumina platforms and 25 percent adopted Oxford Nanopore for real-time sequencing. Over 22 states integrated WGS in newborn screening pilots, impacting more than 80,000 newborns in 2024.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 58 percent of demand in 2024 came from clinical diagnostics applications worldwide.
• Major Market Restraint: 33 percent of small labs cited high sequencing costs as a barrier in 2024.
• Emerging Trends: 27 percent of WGS usage in 2024 was supported by AI-driven analytics, compared with 12 percent in 2021.
• Regional Leadership: North America contributed 37 percent, Europe 28 percent, Asia-Pacific 29 percent, and MEA 6 percent in 2024.
• Competitive Landscape: Illumina held 40 percent share, BGI 12 percent, Oxford Nanopore 10 percent, and Thermo Fisher 8 percent in 2024.
• Market Segmentation: Large genome sequencing accounted for 72 percent, while small genome sequencing represented 28 percent in 2024.
• Recent Development: Over 22 states in the USA integrated WGS into newborn screening programs in 2024.

Whole Genome Sequencing (WGS) Market Latest Trends

The Whole Genome Sequencing (WGS) Market Trends highlight rapid adoption in clinical diagnostics, agriculture, and animal health. In 2024, over 3.8 million genomes were sequenced globally, with 58 percent for clinical diagnostics, 32 percent for research, and 10 percent for agriculture/animal genetics. AI-driven analysis supported 27 percent of genome interpretation, handling more than 10 million variant calls daily. Portable sequencing systems grew by 22 percent in 2024, with Oxford Nanopore’s handheld devices adopted in 80 countries. Cloud-based genomic platforms managed 25 petabytes of sequencing data, with 45 percent of usage from healthcare providers. Multi-omics integration accelerated, with 35 percent of WGS projects combining transcriptomics or proteomics.

Whole Genome Sequencing (WGS) Market Dynamics

DRIVER

"Rising demand for clinical diagnostics."

Clinical diagnostics accounted for 58 percent of sequencing in 2024, representing 2.2 million genomes. Oncology sequencing covered 1.1 million cancer patients globally, improving targeted treatment options. Prenatal and neonatal sequencing expanded to 250,000 newborns in 2024. Rare disease sequencing supported 100,000 patients worldwide, with diagnostic rates rising by 38 percent compared with traditional testing. WGS adoption in infectious disease monitoring increased, with 45,000 pathogen genomes sequenced during outbreaks in 2024.

RESTRAINT

"High sequencing costs for small labs."

Around 33 percent of smaller laboratories reported cost barriers in 2024. Average sequencing cost per genome remained USD 500–600, restricting adoption in low-income settings. In Africa, only 18 sequencing centers operated in 2024, covering less than 5 percent of patient demand. Latin America had 25 sequencing facilities, but 40 percent of them reported underutilization due to financial barriers. Small-scale labs cited infrastructure investment requirements exceeding USD 2 million for WGS integration.

OPPORTUNITY

"Growth in AI-driven genome analytics."

AI-supported genome analysis grew to 27 percent of WGS usage in 2024, compared with 12 percent in 2021. Over 200 AI platforms globally processed 10 million variant calls daily. In Europe, AI improved rare disease diagnostic yield by 22 percent. Asia-Pacific accounted for 40 percent of AI integration, especially in China and India. Around 120,000 patients benefited from AI-based genome reporting in 2024. AI-based analytics reduced reporting turnaround time by 40 percent, from 4 weeks to 2.5 weeks on average.

CHALLENGE

"Data storage and privacy management."

WGS generated over 50 petabytes of genomic data in 2024. Around 35 percent of sequencing centers faced storage limitations. Data security concerns grew, with 22 percent of patients hesitant to share genomic data for clinical trials. In the USA, 14 states reported policy challenges on genomic privacy. Europe invested heavily in GDPR compliance, with 40 percent of sequencing centers upgrading encryption frameworks in 2024. Around 20 percent of labs faced interoperability challenges between sequencing data and electronic health records.

Whole Genome Sequencing (WGS) Market Segmentation

Large whole-genome sequencing dominated with 72 percent share in 2024, covering 2.7 million genomes, while small genome sequencing held 28 percent at 1.1 million. Humanity applications led with 65 percent, followed by plant sequencing at 20 percent and animal sequencing at 15 percent. In total, 2.5 million human genomes were sequenced, alongside 750,000 plant and 550,000 animal genomes. Software-integrated sequencing solutions supported over 70 percent of new workflows in 2024.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Large Whole-Genome Sequencing (> 5 Mb): This segment accounted for 72 percent in 2024. Over 2.7 million human genomes were sequenced, alongside 500,000 plant genomes and 300,000 animal genomes. Clinical diagnostics dominated usage, with oncology and rare diseases representing 1.4 million sequences. Research applications sequenced 900,000 genomes, while agriculture accounted for 200,000.

The large whole-genome sequencing segment is valued at USD 7,380.29 million in 2025, representing 70% share, and projected to reach USD 29,620.79 million by 2034, growing at a CAGR of 16.68% driven by human genome mapping and biomedical applications.

Top 5 Major Dominant Countries in the Large Whole-Genome Sequencing Segment

• United States: USD 2,214.09 million in 2025, 30% share and 16.70% CAGR, supported by clinical adoption and federal genomics projects.
• China: USD 1,844.72 million in 2025, 25% share and 16.72% CAGR, fueled by large-scale genome initiatives.
• Germany: USD 1,107.04 million in 2025, 15% share and 16.67% CAGR, driven by EU research funding.
• Japan: USD 738.02 million in 2025, 10% share and 16.65% CAGR, supported by healthcare genomics integration.
• United Kingdom: USD 738.02 million in 2025, 10% share and 16.66% CAGR, led by precision medicine programs.

Small Genome Sequencing (≤ 5 Mb): Small genomes represented 28 percent of sequencing in 2024, totaling 1.1 million microbial genomes. Pathogen sequencing for infectious diseases contributed 45,000 bacterial genomes during outbreaks. Agricultural microbiome sequencing covered 120,000 genomes in 2024. The USA sequenced 20,000 microbial genomes for antibiotic resistance studies.

The small genome sequencing segment is projected at USD 3,162.99 million in 2025, representing 30% share, and forecasted to reach USD 12,694.63 million by 2034, advancing at a CAGR of 16.72% driven by microbiology, agriculture, and pathogen research.

Top 5 Major Dominant Countries in the Small Genome Sequencing Segment

• United States: USD 948.90 million in 2025, 30% share and 16.71% CAGR, supported by pathogen and microbial genome sequencing.
• China: USD 790.75 million in 2025, 25% share and 16.73% CAGR, driven by agricultural genome projects.
• Germany: USD 474.45 million in 2025, 15% share and 16.68% CAGR, supported by industrial microbiome research.
• Japan: USD 316.30 million in 2025, 10% share and 16.65% CAGR, influenced by plant genome sequencing.
• India: USD 316.30 million in 2025, 10% share and 16.74% CAGR, fueled by public health genome initiatives.

BY APPLICATION

Humanity: Humanity accounted for 65 percent of sequencing, with 2.5 million genomes sequenced in 2024. Clinical diagnostics supported 1.4 million patients with cancer, rare diseases, and prenatal conditions. Research projects sequenced 900,000 human genomes, focusing on genetic variation studies.

The humanity application is valued at USD 6,325.97 million in 2025, accounting for 60% share, expected to grow at 16.70% CAGR, driven by personalized medicine, cancer research, and genetic disorder diagnosis.

Top 5 Major Dominant Countries in the Humanity Application

• United States: USD 1,897.79 million in 2025, 30% share and 16.71% CAGR, driven by precision oncology.
• China: USD 1,518.23 million in 2025, 24% share and 16.73% CAGR, supported by population-wide sequencing.
• Germany: USD 948.90 million in 2025, 15% share and 16.68% CAGR, influenced by EU health projects.
• Japan: USD 632.59 million in 2025, 10% share and 16.65% CAGR, focused on healthcare genomics.
• United Kingdom: USD 632.59 million in 2025, 10% share and 16.67% CAGR, led by NHS genome program adoption.

Plant: Plant sequencing accounted for 20 percent, with 750,000 genomes sequenced in 2024. Major crops sequenced included rice (120,000 genomes), maize (80,000), and wheat (65,000). Genome mapping improved yield efficiency by 18 percent across digitized farms.

The plant genome sequencing application is projected at USD 2,108.66 million in 2025, representing 20% share, expanding at 16.72% CAGR, with demand from agriculture, food security, and crop improvement projects.

Top 5 Major Dominant Countries in the Plant Application

• China: USD 632.59 million in 2025, 30% share and 16.73% CAGR, leading in crop genome projects.
• India: USD 421.73 million in 2025, 20% share and 16.74% CAGR, with agricultural research adoption.
• United States: USD 421.73 million in 2025, 20% share and 16.70% CAGR, supporting agricultural biotech firms.
• Brazil: USD 316.30 million in 2025, 15% share and 16.71% CAGR, focused on soybean and corn genomes.
• Germany: USD 316.30 million in 2025, 15% share and 16.68% CAGR, supporting EU agricultural genomics programs.

Animal: Animal sequencing represented 15 percent, covering 550,000 genomes. Livestock sequencing included cattle (150,000 genomes), poultry (80,000), and swine (50,000). Companion animals contributed 100,000 genomes in 2024. Aquaculture sequencing covered 40,000 fish genomes.

The animal genome sequencing application is valued at USD 2,108.66 million in 2025, holding 20% share, forecasted to expand at 16.71% CAGR, supported by livestock health, veterinary medicine, and biodiversity research.

Top 5 Major Dominant Countries in the Animal Application

• United States: USD 632.59 million in 2025, 30% share and 16.70% CAGR, supported by livestock genome sequencing.
• China: USD 527.17 million in 2025, 25% share and 16.72% CAGR, driven by aquaculture and poultry genome studies.
• Germany: USD 316.30 million in 2025, 15% share and 16.69% CAGR, with veterinary and animal health focus.
• Japan: USD 210.87 million in 2025, 10% share and 16.66% CAGR, driven by pet and biodiversity genomics.
• India: USD 210.87 million in 2025, 10% share and 16.74% CAGR, supported by livestock and dairy animal research.

Whole Genome Sequencing (WGS) Regional Outlook

North America led with 37 percent of demand, sequencing 1.4 million genomes across 420 facilities and 22 states with newborn screening programs. Europe followed with 28 percent at 1.1 million genomes, with 70 percent from the UK, Germany, and France. Asia-Pacific captured 29 percent, sequencing 1.1 million genomes, including 500,000 in China and 200,000 in India, with 350,000 focused on plants. Middle East & Africa held 6 percent, sequencing 200,000 genomes across 18 centers, with Egypt contributing 25,000 plant genomes.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounted for 37 percent of global sequencing, equal to 1.4 million genomes in 2024. The USA represented 90 percent of the region, with 420 sequencing facilities. Around 68 percent of US hospitals integrated WGS for oncology, and 22 states applied it in newborn programs. Canada sequenced 120,000 genomes in 2024, mainly for rare disease research. North America generated 20 petabytes of genomic data in 2024.

North America is projected at USD 3,688.15 million in 2025, representing 35% share and 16.70% CAGR, supported by advanced sequencing facilities, biotechnology firms, and personalized medicine adoption across healthcare systems.

North America - Major Dominant Countries in the Whole Genome Sequencing (WGS) Market

• United States: USD 2,949.12 million in 2025, 80% share and 16.71% CAGR, dominating research and clinical sequencing.
• Canada: USD 368.81 million in 2025, 10% share and 16.68% CAGR, supported by healthcare projects.
• Mexico: USD 221.29 million in 2025, 6% share and 16.69% CAGR, with rising biotech investments.
• Puerto Rico: USD 73.76 million in 2025, 2% share and 16.66% CAGR, focused on niche research.
• Dominican Republic: USD 73.76 million in 2025, 2% share and 16.65% CAGR, showing entry-level adoption.

EUROPE

Europe contributed 28 percent, sequencing 1.1 million genomes in 2024. The UK, Germany, and France accounted for 70 percent of sequencing capacity. Around 38 percent of European hospitals adopted WGS for prenatal care. Rare disease programs sequenced 80,000 patients across the continent. Data centers managed 12 petabytes of genomic data in 2024.

Europe is valued at USD 2,843.64 million in 2025, representing 27% share and 16.68% CAGR, led by EU-funded genomics projects, personalized healthcare, and agricultural genome sequencing advancements.

Europe - Major Dominant Countries in the Whole Genome Sequencing (WGS) Market

• Germany: USD 852.97 million in 2025, 30% share and 16.68% CAGR, with strong research programs.
• United Kingdom: USD 710.91 million in 2025, 25% share and 16.67% CAGR, supported by NHS genomics.
• France: USD 426.55 million in 2025, 15% share and 16.66% CAGR, driven by cancer research.
• Italy: USD 284.36 million in 2025, 10% share and 16.65% CAGR, with clinical sequencing adoption.
• Spain: USD 284.36 million in 2025, 10% share and 16.64% CAGR, supported by agricultural genomics.

ASIA-PACIFIC

Asia-Pacific represented 29 percent, sequencing 1.1 million genomes. China contributed 45 percent of the region, sequencing 500,000 genomes in 2024. India sequenced 200,000 genomes, while Japan and South Korea sequenced 150,000 each. Asia-Pacific led in agricultural genomics, covering 350,000 plant genomes in 2024.

Asia is projected at USD 3,162.99 million in 2025, representing 30% share and 16.72% CAGR, driven by national genome projects, agricultural research, and rising demand for affordable sequencing.

Asia - Major Dominant Countries in the Whole Genome Sequencing (WGS) Market

• China: USD 948.90 million in 2025, 30% share and 16.73% CAGR, dominating genome sequencing.
• India: USD 632.59 million in 2025, 20% share and 16.74% CAGR, supported by genome mapping programs.
• Japan: USD 632.59 million in 2025, 20% share and 16.66% CAGR, focused on medical genomics.
• South Korea: USD 474.45 million in 2025, 15% share and 16.68% CAGR, with biotech expansion.
• Singapore: USD 316.30 million in 2025, 10% share and 16.69% CAGR, supported by research institutions.

MIDDLE EAST & AFRICA

MEA accounted for 6 percent, sequencing 200,000 genomes in 2024. South Africa sequenced 50,000 genomes, while UAE and Saudi Arabia sequenced 40,000 combined. Egypt led in agricultural genomics with 25,000 plant genomes sequenced. MEA generated 2 petabytes of genomic data in 2024, with 18 sequencing centers active.

Middle East and Africa are valued at USD 848.64 million in 2025, representing 8% share with 16.65% CAGR, fueled by healthcare modernization, genomics research centers, and niche agricultural sequencing programs.

Middle East and Africa - Major Dominant Countries in the Whole Genome Sequencing (WGS) Market

• Saudi Arabia: USD 254.59 million in 2025, 30% share and 16.66% CAGR, driven by genome health projects.
• UAE: USD 203.67 million in 2025, 24% share and 16.65% CAGR, with biotech investments.
• South Africa: USD 127.30 million in 2025, 15% share and 16.64% CAGR, leading in genomics research.
• Egypt: USD 101.83 million in 2025, 12% share and 16.63% CAGR, with academic-driven sequencing.
• Nigeria: USD 84.86 million in 2025, 10% share and 16.64% CAGR, supporting agricultural genome initiatives.

List of Top Whole Genome Sequencing (WGS) Companies

• Macrogen
• Agilent Technologies
• Thermo Fisher
• Illumina
• 10x Genomics
• Veritas Genetics
• GENEWIZ
• CD Genomics
• Centogene
• Oxford Nanopore
• BGI
• Berry Genomics
• QIAGEN
• Nebula Genomics
• Psomagen

Top Two Companies by Highest Market Share:

• Illumina held 40 percent of sequencing globally in 2024, sequencing 2.5 million genomes.
• BGI accounted for 12 percent, with 450,000 genomes sequenced, mainly in Asia-Pacific.

Investment Analysis and Opportunities

In 2024, global WGS investment supported 3.8 million genomes sequenced. North America attracted 37 percent of investments, equivalent to 1.4 million sequences. Europe accounted for 28 percent, focusing on prenatal and rare disease programs. Asia-Pacific attracted 29 percent, with China sequencing 500,000 genomes. Opportunities lie in AI integration, which processed 10 million daily variant calls in 2024. Agricultural genomics sequenced 750,000 plant genomes, boosting crop yield efficiency by 18 percent. Animal sequencing reached 550,000 genomes, opening new investment areas in livestock genetics. Data storage investments remain critical, with 50 petabytes of genomic data produced globally in 2024.

New Product Development

Between 2023–2025, more than 150 new sequencing solutions were launched. Illumina introduced high-throughput sequencers processing 20,000 genomes annually. BGI developed rapid sequencing systems achieving 10-hour genome completion. Oxford Nanopore expanded portable devices used in 80 countries. Thermo Fisher launched integrated workflows reducing sequencing preparation by 25 percent. 10x Genomics developed linked-read technologies covering complex genomic regions. These new products cut sequencing time by 30 percent, reduced errors by 15 percent, and expanded access across 120 countries globally.

Five Recent Developments

• Illumina sequenced 2.5 million genomes globally in 2024.
• BGI launched 10-hour rapid sequencing technology in 2024.
• Oxford Nanopore portable devices adopted in 80 countries by 2025.
• Thermo Fisher released workflows reducing prep time by 25 percent in 2024.
• Europe sequenced 80,000 rare disease patients under coordinated programs in 2025.

Report Coverage

The Whole Genome Sequencing (WGS) Market Report covers 3.8 million genomes sequenced in 2024 across healthcare, research, and agriculture. By type: large genome sequencing 72 percent, small genome sequencing 28 percent. By application: humanity 65 percent, plant 20 percent, animal 15 percent. North America accounted for 37 percent, Europe 28 percent, Asia-Pacific 29 percent, and MEA 6 percent. Illumina led with 40 percent share, followed by BGI at 12 percent. Data output surpassed 50 petabytes globally. Investments focused on AI integration, prenatal diagnostics, rare disease sequencing, and agricultural genomics.

Whole Genome Sequencing (WGS) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1227.88 Million in 2026
Market Size Value By	USD 49382.1 Million by 2035
Growth Rate	CAGR of 16.7% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Large Whole-Genome Sequencing (> 5 Mb) Small Genome Sequencing (? 5 Mb) By Application : Humanity Plant Animal
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample